FILTER
FILTERED INTERVIEW RESULTS
Greg Smith
PRESIDENT, TREK MINING
Trek Mining is developing a strong gold portfolio in both processing and mining.
Dr. Quinton Hennigh
CEO & DIRECTOR, NOVO RESOURCES
Novo Resources, based in Vacouver, is developing Gold assets in Australia, set to begin construction at Beatons Creek in 2018.
Jeff Elliott
MANAGING DIRECTOR, CSA GLOBAL
CSA Global is targeting the Americas to further increase the company’s global reach.
Javiera Contreras
MINING & METALS MANAGER, EY
EY in Chile generates a tenth of its revenues from the mining industry.
Juan Pablo González Toledo
PRESIDENT, INSTITUTE OF MINING ENGINEERS OF CHILE
The President of Chile’s Institute of Mining Engineers speaks to GBR of the current issues that Chilean engineers are facing.
Sergio Hernández Núñez
EXECUTIVE VICE PRESIDENT, CHILEAN COPPER COMMISSION (COCHILCO)
Cochilco provides the Chilean copper mining industry with vital strategic information with which to guide strategy.
Nigel Forrester
MANAGING DIRECTOR, MOUNT BURGESS
Mount Burgess’ Kihabe project in Botswana is preparing a feasibility study this year as it aims at significant zinc production.
Pedro Damjanic
SENIOR VP OF MINING, FINNING CHILE
Finning Chile explains how its Caterpillar equipment business adapted to current conditions and how it envisages the next.
James Hume
PRESIDENT, EAGLE MAPPING
Eagle Mapping are busy Lidar scanning the northern parts of B.C. and Yukon from the air.
Stephen Keith
PRESIDENT, GROWMAX RESOURCES
Recently re-branded GrowMax Resources explains how it intend to develop its fertilizer assets in Peru.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
